Krazati® (adagrasib)
for Lung Cancer

Krazati (adagrasib) is a targeted therapy for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) with a KRAS G12C mutation. It works by inhibiting the KRAS G12C protein, locking it in an inactive state to help stop tumor growth. The KRAS gene regulates cell growth, and mutations can lead to uncontrolled cancer cell proliferation. Krazati is taken as oral tablets twice daily to reduce tumor progression.

Heart